stoxline Quote Chart Rank Option Currency Glossary
Cryo-Cell International, Inc. (CCEL)
8.81  -0.39 (-4.24%)    05-30 16:00
Open: 9.01
High: 9.1799
Volume: 5,699
Pre. Close: 9.2
Low: 8.81
Market Cap: 71(M)
Technical analysis
2024-05-30 4:40:25 PM
Short term     
Mid term     
Targets 6-month :  11.09 1-year :  12.95
Resists First :  9.49 Second :  11.09
Pivot price 9.06
Supports First :  8.41 Second :  7.75
MAs MA(5) :  9.07 MA(20) :  8.97
MA(100) :  6.74 MA(250) :  6.02
MACD MACD :  0.3 Signal :  0.3
%K %D K(14,3) :  57.2 D(3) :  62
RSI RSI(14): 53.6
52-week High :  9.49 Low :  3.67
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ CCEL ] has closed above bottom band by 4.8%. Bollinger Bands are 58.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 9.19 - 9.24 9.24 - 9.28
Low: 8.7 - 8.75 8.75 - 8.8
Close: 8.72 - 8.81 8.81 - 8.89
Company Description

Cryo-Cell International, Inc. engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, and auto-immune diseases. The company also manufactures and sells PrepaCyte CB processing system, a technology used to process umbilical cord blood stem cells. It stores approximately 500,000 cord blood and cord tissue stem cells worldwide. The company markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. Cryo-Cell International, Inc. was incorporated in 1989 and is headquartered in Oldsmar, Florida.

Headline News

Tue, 26 Mar 2024
Cryo-Cell International Announces Strategic Subsidiary Spin-Off Plans - - TipRanks

Mon, 25 Mar 2024
Cryo-Cell Announces Plans to Explore Strategic Alternatives and Spin-off Celle Corp. to Maximize Shareholder Value - Business Wire

Sun, 24 Mar 2024
CCEL Stock Quote Price and Forecast - CNN

Wed, 31 Aug 2022
CCEL Stock Price and Chart — AMEX:CCEL — TradingView - TradingView

Mon, 30 Aug 2021
Cryo-Cell International Announces Uplisting to The Nasdaq Capital Market - GlobeNewswire

Fri, 26 Feb 2021
Cord Blood Banking Leader Cryo-Cell International Enters Into An Exclusive License Agreement with Duke University - GlobeNewswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Medical - Care Facilities
Shares Out 8 (M)
Shares Float 4 (M)
Held by Insiders 46.1 (%)
Held by Institutions 10.1 (%)
Shares Short 17 (K)
Shares Short P.Month 18 (K)
Stock Financials
EPS 0.3
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -0
Profit Margin 8 %
Operating Margin 16.3 %
Return on Assets (ttm) 4 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth 2.5 %
Gross Profit (p.s.) 2.59
Sales Per Share 3.76
EBITDA (p.s.) 0.7
Qtrly Earnings Growth 43.7 %
Operating Cash Flow 8 (M)
Levered Free Cash Flow -9 (M)
Stock Valuations
PE Ratio 29.36
PEG Ratio 0
Price to Book value 0
Price to Sales 2.33
Price to Cash Flow 9.11
Stock Dividends
Dividend 0.89
Forward Dividend 0
Dividend Yield 10.2%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android